NUCRYST Pharmaceuticals has created a Board of Directors with a broad base of experience to guide business strategy and practices
Neil Carragher - Barry M. Heck - Richard W. Zahn
Neil Carragher became a director in December 2005 and became Chairman of the Board in January 2009. Mr. Carragher has been the Chairman of The Corporate Partnership Ltd., a management consulting group, for more than five years. Mr. Carragher is a director of Westaim and Agrium Inc. Mr. Carragher holds a B.Sc. from the University of Glasgow and a M.Sc. from the University of London.
Barry M. Heck has served as a director since incorporation. Mr. Heck has held a variety of senior executive positions at The Westaim Corporation over the past 10 years. Most recently he held the position of President and CEO of Westaim, playing a pivotal role in NUCRYST's 2005 Initial Public Offering. Mr. Heck also serves on the board of directors for several other public and private companies. He holds a law degree from the University of Alberta.
Richard W. Zahn became a director in December 2005. From 1992 to 2003, Mr. Zahn held numerous senior management positions within the Schering-Plough Corporation, a global research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical biotechnology products and health care products, including President of Schering Laboratories and Corporate Vice President of Schering-Plough Corporation. Schering Laboratories is the US prescription marketing arm for Schering-Plough. Mr. Zahn is a director of Norwood Abbey Ltd and Norwood Immunology Ltd. Mr. Zahn holds a BS in Business Administration from Kansas State Teachers College.
|
